Future ‘up in the air’ for luveltamab tazevibulin as treatment for ovarian cancer

Source:
Healio interviews

Disclosures:
Matulonis reports consulting fees from Merck; data safety monitoring board participation for Mural Oncology and Symphogen; and scientific advisory board participation for Abbvie, Allarity, Daiichi Sankyo, Eisai, GSK, Immunogen, NextCure, Novartis, Profound Bio, Tango Therapeutics and the Ovarian Cancer Research Alliance.